Saturday 17 October 2026 Export EDSA’s income statement to Excel — free account

Edesa Biotech, Inc.

In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.57 0.10 −3.75%

Follow EDSA

Alert me

Market cap: $36.1M
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 3/9
Altman Z: 22.29
Beneish M: −4.36
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.23

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	2	5	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 36.08

Revenue 0.33

Net Income (14.10)

Free Cash Flow (8.91)

Net Debt (10.33)

Current Ratio 2.76

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.09)

P/S ratio 70.40

P/B ratio 58.02

Past 5Y EPS Growth —

This Y EPS Growth (56.43%)

Next Y EPS Growth (4.03%)

Next Y revenue growth (100.00%)

Next 5Y EPS Growth (17.31%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 63.29%

10-year low 10-year high

P/B against its own 10 years 96.61%

10-year low 10-year high

EV/Sales against its own 10 years 56.38%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	1	11	10
Receivables	1	0	1	0
Inventory	—	—	—	—
Other	—	—	—	—
	6	2	12	11

	2023	2024	2025	Q'26
Payables	2	2	1	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	1	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	(15.40%)	12.93%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.52%	6.45%	9.86%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	—	—	—	—	—
’20	0	0	0	0	0
’19	0	0	0	0	0
’18	0	0	—	0	0
’17	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(2)	(2)	(3)	—	—
’25	(2)	(2)	(2)	(2)	(7)
’24	(1)	(2)	(1)	(1)	(5)
’23	(2)	(2)	(2)	(1)	(7)
’22	(3)	0	(3)	(6)	(12)
’21	(3)	(7)	(3)	0	(14)
’20	(1)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(2)	(2)	(3)	—	—
’25	(2)	(2)	(2)	(2)	(7)
’24	(1)	(2)	(1)	(1)	(5)
’23	(2)	(2)	(2)	(1)	(7)
’22	(3)	0	(3)	(6)	(12)
’21	(3)	(7)	(3)	0	(14)
’20	(1)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.28)	(0.49)	(0.60)	—	—
’25	(0.48)	(0.30)	(0.25)	(0.32)	(1.27)
’24	(0.54)	(0.58)	(0.52)	(0.29)	(1.93)
’23	(0.91)	(0.84)	(0.70)	(0.54)	(2.93)
’22	(2.31)	(2.31)	(2.59)	(1.15)	(7.35)
’21	(1.82)	(1.33)	(2.52)	(1.89)	(7.70)
’20	(1.05)	(1.19)	(1.40)	(1.54)	(5.18)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	526.26	220.50	31.50	22.96	11.06	28.35	5.32	2.46	1.55	1.28	Analyst estimates 2026–2028 Powerpack
	High	2,037.42	652.68	320.46	121.80	133.70	84.00	43.05	19.67	5.99	4.49
People
People	Employees	23	28	25	—	12	16	16	16	16	17
	Revenue/emp, $m	0.06	0.01	0.01	0.00	0.03	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	0	0	0	0	—	—	—	—	—
	Gross margin, %	11.32	(134.12)	(110.25)	75.35	94.65	0.00	0.00	0.00	—	—
	EBT	(5)	(5)	(5)	(3)	(6)	(13)	(18)	(8)	(6)	(7)
	EBT margin, %	(394.66)	(2,203.15)	(2,378.71)	(675.76)	(1,935.34)	0.00	0.00	0.00	0.00	0.00
	Net income	(5)	(5)	(5)	0	(6)	(13)	(18)	(8)	(6)	(7)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	42.39	6.56	3.10	0.57	0.27	0.00	0.00	0.00	0.00	0.00
	Earnings	(167.45)	(143.94)	(73.88)	(3.86)	(5.18)	(7.70)	(7.35)	(2.93)	(1.93)	(1.27)
	Cash flow	(150.19)	(135.05)	(67.58)	(6.73)	(4.05)	(7.92)	(5.86)	(2.32)	(1.53)	(1.29)
	Capex	(13.41)	(8.70)	(5.60)	0.00	0.02	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(163.60)	(143.74)	(73.18)	(6.73)	(4.04)	(7.92)	(5.86)	(2.32)	(1.53)	(1.29)
	Book value	410.47	212.62	165.25	7.30	7.41	7.57	4.48	2.47	0.62	2.19
	Shares, m	0	0	0	1	1	2	2	3	3	6
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	P/S	16.65	51.09	18.56	53.95	211.30	—	—	—	—	—
	P/B	1.72	1.58	0.35	5.97	10.48	—	—	—	—	—
	EV/Sales	7.68	22.33	(29.41)	45.30	189.37	—	—	—	—	—
	EV/FCF	(1.99)	(1.02)	1.26	(3.22)	(12.61)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(5)	(5)	(5)	(5)	(5)	(14)	(12)	(7)	(5)	(7)
	Capex	0	0	0	0	0	0	0	—	—	—
	Free cash flow	(5)	(5)	(5)	(5)	(5)	(14)	(12)	(7)	(5)	(7)
Balance, $m
Balance, $m	Working capital	11	6	10	5	7	11	7	5	0	10
	Total debt	—	—	—	—	0	0	0	0	—	—
	Net debt	(11)	(7)	(10)	(5)	(7)	(8)	(7)	(5)	(1)	(11)
	Shareholders’ equity	12	7	11	5	9	13	9	7	2	12
Returns, %
Returns, %	ROA	(43.10)	(48.70)	(51.68)	(31.74)	(77.23)	(105.28)	(134.16)	(81.84)	(97.13)	(82.86)
	ROIC	(337.67)	(391.67)	(322.88)	(784.95)	(211.18)	(283.59)	(499.12)	(341.61)	(464.48)	(297.91)
	ROE	(49.47)	(51.04)	(53.93)	(33.57)	(107.08)	(135.54)	(156.34)	(101.88)	(136.66)	(277.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2020 · latest quarter Sep 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LBPS 4D pharma PLC Sponsored ADR	$37.2M	— (loss-making)	—	+41.64% (above 0%: growing)	n/m	−16,367.69% (below 0%: shrinking)	0.00%	0.00%	Compare
EXOZ eXoZymes Inc.	$37.1M	— (loss-making)	—	—	n/m	−3.25% (below 0%: shrinking)	—	0.00%	Compare
FLNA Cassava Sciences, Inc.	$36.8M	— (loss-making)	—	+1,328.04% (above 0%: growing)	n/m	+21.65% (above 0%: growing)	0.00%	0.00%	Compare
LITS Lite Strategy, Inc.	$36.3M	— (loss-making)	— (loss-making)	+647.96% (above 0%: growing)	n/m	+179.28% (above 0%: growing)	0.00%	0.00%	Compare
EDSA Edesa Biotech, Inc.	$36.1M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$35.7M	—	—	+344.80%	—	−4.72%	0.00%	0.00%

All 614 Biotechnology stocks →

Edesa Biotech, Inc. (EDSA) key facts

Edesa Biotech, Inc. (EDSA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, EDSA traded at $2.57, a market capitalization of $36.1 million.
Return on equity was −277.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.